AMAG Pharmaceuticals Appoints Carol Satler, M.D., Ph.D. as Senior Vice President of Medical and Scientific Affairs
23 juil. 2013 08h00 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Carol Satler, M.D, Ph.D. as senior vice president of medical and...
AMAG Pharmaceuticals Appoints Amit Verma as Vice President of Marketing
03 juil. 2013 08h30 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., July 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Amit Verma as vice president of marketing. Mr. Verma comes to AMAG with...
New Campaign Wants Patients to Know "Iron Matters"
24 juin 2013 08h30 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- In response to a recent national survey finding that three-quarters of Americans don't fully understand the role that iron plays in the body,1 AMAG...
AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and Regulatory Officer
24 juin 2013 08h00 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Steven Caffé, M.D. as senior vice president and chief development...
AMAG Pharmaceuticals Obtains US Commercial Rights to MuGard(TM) A Prescription Oral Rinse to Manage Oral Mucositis
10 juin 2013 08h00 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., June 10, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has licensed the US commercial rights to MuGard™, a marketed product for the...
AMAG Pharmaceuticals Announces Submission of a Type II Variation for Rienso Label Expansion in Europe to Include All Adult Iron Deficiency Anemia Patients Who Cannot Take Oral Iron
07 juin 2013 08h45 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., June 7, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that its European commercial partner, Takeda Pharmaceutical Company Limited, has submitted a...
AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
03 juin 2013 08h30 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., June 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Jefferies 2013...
Ferumoxytol Treatment Produced Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed or Could Not Tolerate Oral Iron Therapy
21 mai 2013 08h30 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., May 21, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced that a new sub-group analysis from IDA-301, a phase III, randomized, placebo-controlled clinical...
Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy
06 mai 2013 08h30 HE
|
AMAG Pharmaceuticals, Inc.
LEXINGTON, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that a new sub-group analysis from IDA-301, a phase III, randomized, placebo-controlled...